生长抑素联合泮托拉唑钠治疗重症急性胰腺炎的临床观察

发布时间：2018-05-02 02:34

本文选题：生长抑素 + 泮托拉唑钠　；参考：《中国药房》2015年18期

【摘要】：目的:研究生长抑素联合泮托拉唑钠治疗重症急性胰腺炎的临床疗效和安全性。方法:回顾性分析98例重症急性胰腺炎患者资料,按用药的不同分为对照组和观察组。两组患者均行常规治疗。与此同时,对照组患者给予注射用泮托拉唑钠40 mg加入0.9%氯化钠注射液100 ml中,静脉滴注,bid;观察组患者在对照组治疗基础上,加用注射用生长抑素3 mg加入0.9%氯化钠注射液500 ml中,以0.25 mg/h的速度通过微量静脉泵持续静脉泵入,bid。两组患者疗程均为7 d。观察两组患者的临床疗效,症状体征改善时间(腹痛缓解时间、肠道功能恢复时间、脱离呼吸机时间),治疗前后肿瘤坏死因子α(TNF-α)、高敏C反应蛋白(hs-CRP)、白细胞介素8(IL-8)水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,症状体征改善时间显著短于对照组,差异均有统计学意义(P0.05)。治疗后,两组患者炎症因子水平均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P0.05)。观察组患者不良反应发生率显著低于对照组,差异有统计学意义(P0.05)。结论:在常规治疗基础上以生长抑素联合泮托拉唑钠治疗重症急性胰腺炎较单用泮托拉唑钠疗效更显著,且安全性更好。
[Abstract]:Objective: To study the clinical efficacy and safety of somatostatin combined with pantoprazole sodium in the treatment of severe acute pancreatitis. Methods: the data of 98 patients with severe acute pancreatitis were analyzed retrospectively. The control group and the observation group were divided into the control group and the observation group according to the different medication. In the same time, the control group was given Pantoprazole Sodium for Injection 40. Mg was added to 0.9% Sodium Chloride Injection 100 ml, intravenous drip, and bid; on the basis of the control group, the patients in the observation group were added to 0.9% Sodium Chloride Injection 500 ml with Somatostatin for Injection 3 mg, and the intravenous pump was continuously pumped at a speed of 0.25 mg/h, and the patients of the bid. two group were treated with 7 d. to observe the clinical efficacy of the two groups. Symptoms and signs improvement time (abdominal pain relief time, intestinal function recovery time, ventilator time), tumor necrosis factor alpha (TNF- alpha), high sensitive C reactive protein (hs-CRP), interleukin 8 (IL-8) level and adverse reaction occurred. Results: the total effective rate of the patients in the observation group was significantly higher than that of the control group, and the time of symptoms and signs was improved. Significantly shorter than the control group, the difference was statistically significant (P0.05). After treatment, the level of inflammatory factors in the two groups was significantly lower than the same group, and the observation group was lower than the control group, the difference was statistically significant (P0.05). The incidence of adverse reactions in the observation group was significantly lower than the control group, the difference was statistically significant (P0.05). Conclusion: in routine On the basis of treatment, somatostatin combined with pantoprazole sodium is more effective and safe in the treatment of severe acute pancreatitis than pantoprazole alone.

【作者单位】：江山市人民医院药剂科;江山市人民医院内科;
【分类号】：R576

【参考文献】